deferoxamine has been researched along with Hepatitis B in 8 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hepatitis B: INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A total of 27 patients with chronic hepatitis B viral infection, who had elevated serum ferritin levels, were randomized to receive either IFN 5 MU, three times weekly by subcutaneous injection alone (n = 14) or in combination with cycles of deferoxamine at a dose od 80 mg kg-1 per cycle (n = 13) administered over 3 consecutive days, to reduce their iron and maintain a serum ferritin level less than 250 ng ml-1." | 9.08 | The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. ( Bayraktar, Y; De Maria, N; Kayhan, B; Koseoglu, T; Somner, C; Temizer, A; Uzunalimoglu, B; Van Thiel, DH, 1996) |
| "In this report we firstly describe a case of reactivation of hepatitis B virus (HBV) replication occurred in a patient affected by Thalassemia major which underwent a combined chelation therapy with desferioxamine (DFO) and deferiprone (DFP)." | 7.75 | Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. ( Ammirabile, M; Cinque, P; Di Matola, T; Lanza Galeota, A; Prossomariti, L; Ricchi, P, 2009) |
| " A total of 27 patients with chronic hepatitis B viral infection, who had elevated serum ferritin levels, were randomized to receive either IFN 5 MU, three times weekly by subcutaneous injection alone (n = 14) or in combination with cycles of deferoxamine at a dose od 80 mg kg-1 per cycle (n = 13) administered over 3 consecutive days, to reduce their iron and maintain a serum ferritin level less than 250 ng ml-1." | 5.08 | The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. ( Bayraktar, Y; De Maria, N; Kayhan, B; Koseoglu, T; Somner, C; Temizer, A; Uzunalimoglu, B; Van Thiel, DH, 1996) |
| "In this report we firstly describe a case of reactivation of hepatitis B virus (HBV) replication occurred in a patient affected by Thalassemia major which underwent a combined chelation therapy with desferioxamine (DFO) and deferiprone (DFP)." | 3.75 | Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier. ( Ammirabile, M; Cinque, P; Di Matola, T; Lanza Galeota, A; Prossomariti, L; Ricchi, P, 2009) |
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| "Hemochromatosis was noted in 4 patients (group II)." | 1.26 | [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)]. ( Bonn, F; Guezennec, M; Simon, P; Tanquerel, T, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ricchi, P | 1 |
| Cinque, P | 1 |
| Lanza Galeota, A | 1 |
| Di Matola, T | 1 |
| Ammirabile, M | 1 |
| Prossomariti, L | 1 |
| Wu, SF | 1 |
| Peng, CT | 1 |
| Wu, KH | 1 |
| Tsai, CH | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| De Virgiliis, S | 1 |
| Argiolu, F | 1 |
| Rais, M | 1 |
| Cossu, P | 1 |
| Toccafondi, C | 1 |
| Sanna, G | 1 |
| Cornacchia, G | 1 |
| Nucaro, A | 1 |
| Ferreli, A | 1 |
| Cao, A | 1 |
| Girot, R | 1 |
| Triadou, P | 1 |
| Bories, D | 1 |
| Jeannel, F | 1 |
| Thevenin, M | 1 |
| Rymer, JC | 1 |
| Simon, P | 1 |
| Bonn, F | 1 |
| Guezennec, M | 1 |
| Tanquerel, T | 1 |
| Locasciulli, A | 1 |
| Monguzzi, W | 1 |
| Tornotti, G | 1 |
| Bianco, P | 1 |
| Masera, G | 1 |
| Bayraktar, Y | 1 |
| Koseoglu, T | 1 |
| Somner, C | 1 |
| Kayhan, B | 1 |
| Temizer, A | 1 |
| Uzunalimoglu, B | 1 |
| De Maria, N | 1 |
| Van Thiel, DH | 1 |
1 trial available for deferoxamine and Hepatitis B
| Article | Year |
|---|---|
The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Chronic Disease; Deferoxamine; DNA, Viral; Drug Syner | 1996 |
7 other studies available for deferoxamine and Hepatitis B
| Article | Year |
|---|---|
Hepatitis B virus reactivation during combined therapy with deferiprone and desferioxamine in a hepatitis B surface antigen thalassemic carrier.
Topics: Adult; Blood Transfusion; Deferiprone; Deferoxamine; Hepatitis B; Hepatitis B virus; Humans; Iron Ch | 2009 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
Therapy of HBsAg-negative chronic active hepatitis in transfusion-dependent thalassemia major.
Topics: Aspartate Aminotransferases; Child; Child, Preschool; Deferoxamine; Hepatitis B; Hepatitis B Surface | 1982 |
[Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major].
Topics: Adolescent; Adult; Blood Group Incompatibility; Child; Child Development; Child, Preschool; Deferoxa | 1982 |
[Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
Topics: Adult; Aged; Biopsy, Needle; Deferoxamine; Female; Ferritins; Hemochromatosis; Hemosiderosis; Hepati | 1981 |
Hepatitis C virus infection and liver disease in children with thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Child, Preschool; Combined Modality T | 1993 |